EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence

Amal Fawzy, Karima M Sweify, Hany M El-Fayoumy, Nagwa Nofal

Journal of the Egyptian National Cancer Institute · 2016-12 · 28 (4) · 235-242

DOI: 10.1016/j.jnci.2016.08.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Egyptian National Cancer Institute, 2016-12. Verfasst von Amal Fawzy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of clinical and Chemical Pathology, National Cancer Institute, Cairo University, Egypt. Electronic address: amalfawzy69@hotmail.com. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Prostate cancer (PC) is the most common cancer affecting men, it accounts for 29% of all male cancer and 11% of all male cancer related death. DNA is normally released from an apoptotic source which generates small fragments of cell-free DNA, whereas cancer patients have cell-free circulating DNA that originated from necrosis, autophagy, or mitotic catastrophe, which produce large fragments. AIM OF WORK: Differentiate the cell free DNA levels (cfDNA) and its integrity in prostate cancer patients and control group composed of benign prostate hyperplasia (BPH) and healthy persons. METHODOLOGY: cf-DNA levels were quantified by real-time PCR amplification in prostate cancer patients (n= 50), (BPH) benign prostate hyperplasia (n= 25) and healthy controls (n= 30) using two sets of ALU gene (product size of 115bp and 247-bp) and its integrity was calculated as a ratio of qPCR results of 247bp ALU over 115bp ALU. RESULTS: Highly significant levels of cf-DNA and its integrity in PC patients compared to BPH. Twenty-eight (56%) patients with prostate cancer had bone metastasis. ALU115 qpcr is superior to the other markers in discriminating metastatic patients with a sensitivity of 96.4% and a specificity of 86.4% and (AUC=0.981) CONCLUSION: ALU115 qpcr could be used as a valuable biomarker helping in identifying high risk patients, indicating early spread of tumor cells as a potential seed for future metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultAlu ElementsBiomarkers, TumorDNA, NeoplasmFemaleHumansMaleMiddle AgedNeoplasm MetastasisPrognosisProstatic HyperplasiaProstatic NeoplasmsRisk Factors

Stichwörter der Autor:innen

ALU sequenceCancer prostateDNA integrityPlasma cell-free DNA

Substanzen

Biomarkers, TumorDNA, Neoplasm

Autor:innen und Institutionen

  • Department of clinical and Chemical Pathology, National Cancer Institute, Cairo University, Egypt. Electronic address: amalfawzy69@hotmail.com.
  • Department of Women's College for Arts, Science and Education, Ain Shams University, Egypt.
  • Department of Urology, Faculty of Medicine Kasr Al-Ainy, Cairo University, Egypt.

Zitieren

APA

Fawzy, A., Sweify, K. M., El-Fayoumy, H. M., & Nofal, N. (2016). Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence. Journal of the Egyptian National Cancer Institute, 28(4), 235-242. https://doi.org/10.1016/j.jnci.2016.08.003

Vancouver

Fawzy A, Sweify KM, El-Fayoumy HM, Nofal N. Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence. Journal of the Egyptian National Cancer Institute. 2016;28(4):235-242. doi:10.1016/j.jnci.2016.08.003

BibTeX
@article{Fawzy2016,
  author = {Fawzy, Amal and Sweify, Karima M and El-Fayoumy, Hany M and Nofal, Nagwa},
  title = {Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence},
  journal = {Journal of the Egyptian National Cancer Institute},
  year = {2016},
  volume = {28},
  number = {4},
  pages = {235--242},
  doi = {10.1016/j.jnci.2016.08.003}
}
Kostenlos starten →